Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group

Tsang, Richard W.; Campbell, Belinda A.; Goda, Jayant Sastri; Kelsey, Chris R.; Kirova, Youlia; Parikh, Rahul R.; Ng, Andrea K.; Ricardi, Umberto; Suh, Chang Ok; Mauch, Peter; Specht, Lena; Yahalom, Joachim

doi:10.1016/j.ijrobp.2018.05.009

Cited by 156 publications

(169 citation statements)

References 79 publications

Supporting

Mentioning

155

Contrasting

Unclassified

Order By: Relevance

“…Radical surgery is recommended to be avoided in head and neck EMP, as radiotherapy is the main treatment. EMP tumors are highly radio-sensitive with longstanding local control of 79 to 91% after radiation therapy [9]. Based on the International Lymphoma Radiation Oncology Group (ILROG) [9], there is still no well-developed standardized radiation dosage.…”

Section: Discussionmentioning

confidence: 99%

“…EMP tumors are highly radio-sensitive with longstanding local control of 79 to 91% after radiation therapy [9]. Based on the International Lymphoma Radiation Oncology Group (ILROG) [9], there is still no well-developed standardized radiation dosage. However, 40 to 45 Gy is the common dosage used in clinical practice [9].…”

Section: Discussionmentioning

confidence: 99%

“…Based on the International Lymphoma Radiation Oncology Group (ILROG) [9], there is still no well-developed standardized radiation dosage. However, 40 to 45 Gy is the common dosage used in clinical practice [9]. Studies have shown that local control rate with 40 Gy and above was 94%; whereas with dosages less than 40 Gy, the local control rate lowered to 69% [9].…”

Section: Discussionmentioning

confidence: 99%

“…However, 40 to 45 Gy is the common dosage used in clinical practice [9]. Studies have shown that local control rate with 40 Gy and above was 94%; whereas with dosages less than 40 Gy, the local control rate lowered to 69% [9]. Therefore, the current guidelines for radiation therapy of EMP suggest the dosage of 40 to 50 Gy.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Localized Extramedullary Plasmacytoma: A Report of Two Cases

et al. 2018

View full text Add to dashboard Cite

Extramedullary plasmacytoma (EMP) is a rare form of plasma cell neoplasm that originates from B lymphocytes. It accounts for only 4% of all plasma cell disorders. We present two cases of EMP that were diagnosed in two different locations. The first case is a 55-yearold presented with epistaxis and sinusoidal polyps. Histologic examination disclosed plasmacytoma. The second case is a 69-year-old patient presented with upper airway obstruction caused by laryngeal mass and histologic examination revealed plasmacytoma of the larynx. Our cases are unique in their presentation and anatomic locations. To our knowledge, sinusoidal and laryngeal occurrences of the disease are only reported in a handful of cases. Both cases were treated mainly with radiotherapy. The postoperative phase was uneventful.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Localized Extramedullary Plasmacytoma: A Report of Two Cases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The International Lymphoma Radiation Oncology Group (ILROG) is a well-recognized worldwide organization of radiation oncologists with a record of producing guidelines for modern RT of these diseases that have become standard. [3][4][5][6][7][8][9][10][11][12][13] With the present guidelines, ILROG aims to help radiation oncologists treating hematological malignancies make rational choices regarding possible changes to reduce the pressure on RT institutions in the current emergency situation. With regard to treatment techniques, keeping those with which the staff is familiar is recommended.…”

Section: Introductionmentioning

confidence: 99%

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Yahalom

Dabaja

Ricardi

et al. 2020

Blood

Self Cite

View full text Add to dashboard Cite

The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.

show abstract

Diagnosis and Management of Multiple Myeloma

Cowan

Green

Kwok

et al. 2022

JAMA

514

272

View full text Add to dashboard Cite

ultiple myeloma is a hematologic malignancy characterized by abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth causing destructive osseous bone lesions, acute kidney injury, anemia, and hypercalcemia. The median age at onset of multiple myeloma is 69 years, and approximately 63% of patients diagnosed with multiple myeloma are older than 65 years. 1 In 2021, an estimated 34 290 new diagnoses of multiple myeloma and 12 410 deaths occurred in the US. In 2019, more than 155 688 people were diagnosed with multiple myeloma worldwide. 2 Approximately 100 000 deaths from multiple myeloma occur each year worldwide. 1 This review summarizes current evidence regarding the epidemiology, clinical presentation, diagnosis, and management of multiple myeloma. MethodsA literature search of the PubMed database was performed between January 1, 2000, through October 6, 2021, for Englishlanguage studies of the epidemiology, diagnosis, clinical presentation, and treatment of multiple myeloma. Additional papers were identified from review of the references from identified relevant articles. A total of 111 reports were identified and reviewed. IMPORTANCE Multiple myeloma is a hematologic malignancy characterized by presence of abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth causing destructive bone lesions, kidney injury, anemia, and hypercalcemia. Multiple myeloma is diagnosed in an estimated 34 920 people in the US and in approximately 588 161 people worldwide each year. OBSERVATIONS Among patients with multiple myeloma, approximately 73% have anemia, 79% have osteolytic bone disease, and 19% have acute kidney injury at the time of presentation. Evaluation of patients with possible multiple myeloma includes measurement of hemoglobin, serum creatinine, serum calcium, and serum free light chain levels; serum protein electrophoresis with immunofixation; 24-hour urine protein electrophoresis; and full-body skeletal imaging with computed tomography, positron emission tomography, or magnetic resonance imaging. The Revised International Staging System combines data from the serum biomarkers β 2 microglobulin, albumin, and lactate dehydrogenase in conjunction with malignant plasma cell genomic features found on fluorescence in situ hybridization-t(4;14), del(17p), and t(14;16)-to assess estimated progression-free survival and overall survival. At diagnosis, 28% of patients are classified as having Revised International Staging stage I multiple myeloma, and these patients have a median 5-year survival of 82%. Among all patients with multiple myeloma, standard first-line (induction) therapy consists of a combination of an injectable proteasome inhibitor (ie, bortezomib), an oral immunomodulatory agent (ie, lenalidomide), and dexamethasone and is associated with median progression-free survival of 41 months, compared with historical reports of 8.5 months without therapy. This induction therapy combined with autologous hematopoietic stem cell transplantation followed by...

show abstract

Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group

Cited by 156 publications

References 79 publications

Localized Extramedullary Plasmacytoma: A Report of Two Cases

Localized Extramedullary Plasmacytoma: A Report of Two Cases

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Diagnosis and Management of Multiple Myeloma

Contact Info

Product

Resources

About